Carbon ion radiotherapy for treatment of prostate cancer and subsequent outcomes after biochemical failure

Anticancer Res. 2010 Dec;30(12):5105-11.

Abstract

Background/aim: Carbon ion radiotherapy is expected to be suitable to treat localized prostate cancer because it yields great biological and physical effects. The aim of this study was to examine long-term results and subsequent outcomes after biochemical failure.

Patients and methods: A total of 254 patients were treated from the beginning of 2003 and followed through 2009. Long-term hormone therapy was also used for some intermediate-risk and high-risk patients.

Results: Among the patients examined, 54 patients experienced biochemical failure. Failure-free survival was 76%, 91% and 76% at eight years in low-risk, intermediate-risk and high-risk patients, respectively. Clinical progression occurred only in high-risk patients, with 89% progression-free survival at eight years. After biochemical failure, diseases of most patients were well controlled by salvage therapy but twelve high-risk patients (5%) died of prostate cancer.

Conclusion: Carbon ion radiotherapy had an excellent effect on localized prostate cancer. Factors influencing salvage therapy included PSA kinetics and duration between radiation and failure.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy*
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Carbon Radioisotopes / chemistry
  • Carbon Radioisotopes / therapeutic use
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Heavy Ion Radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Risk Factors
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Carbon Radioisotopes